Literature DB >> 15023279

Drug Interactions Among the Antiretrovirals.

Ian R. McNicholl1.   

Abstract

There are 20 antiretroviral agents approved by the US Food and Drug Administration (FDA), four of which were approved in 2003. With 20 antiretrovirals FDA-approved, interactions occur when the medications alter the toxicity profile or efficacy of the other medication. In order to maintain clinical relevance, only the most significant interactions published within the past 12 months are highlighted in this article. Interactions discussed involve atazanavir, fosamprenavir, lopinavir/ritonavir, tenofovir, proton pump inhibitors, H(2)-blockers, clarithromycin, and vardenafil. Important interaction-management strategies also are discussed. The field of HIV pharmacology is constantly advancing, as are the drug interaction data. To screen, manage, dose adjust, and counsel, the physician and other health care professionals are highly advised and encouraged to consult with an infectious disease clinical pharmacist when managing patients receiving highly active antiretroviral therapy.

Entities:  

Year:  2004        PMID: 15023279     DOI: 10.1007/s11908-996-0013-9

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  8 in total

Review 1.  Interactions among drugs for HIV and opportunistic infections.

Authors:  S C Piscitelli; K D Gallicano
Journal:  N Engl J Med       Date:  2001-03-29       Impact factor: 91.245

Review 2.  Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

Authors:  M T Huisman; J W Smit; A H Schinkel
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

Review 3.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Update: clinically significant cytochrome P-450 drug interactions.

Authors:  E L Michalets
Journal:  Pharmacotherapy       Date:  1998 Jan-Feb       Impact factor: 4.705

Review 5.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 6.  Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Authors:  G K Dresser; J D Spence; D G Bailey
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 7.  Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.

Authors:  J G Gerber
Journal:  Clin Infect Dis       Date:  2000-06       Impact factor: 9.079

Review 8.  Factors affecting the clinical development of cytochrome p450 3A substrates.

Authors:  Megan A Gibbs; Natilie A Hosea
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  8 in total
  2 in total

1.  Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.

Authors:  John E Ray; Debbie Marriott; Mark T Bloch; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

2.  Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.

Authors:  Maria Concetta Postorino; Mattia Prosperi; Emanuele Focà; Eugenia Quiros-Roldan; Elisa Di Filippo; Franco Maggiolo; Alberto Borghetti; Nicoletta Ladisa; Massimo Di Pietro; Andrea Gori; Laura Sighinolfi; Angelo Pan; Nicola Mazzini; Carlo Torti
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.